ITeos Therapeutics Analyst Ratings
ITeos Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/13/2023 | 213.17% | JP Morgan | $32 → $29 | Maintains | Overweight |
10/18/2023 | 256.37% | Wedbush | → $33 | Reiterates | Outperform → Outperform |
08/09/2023 | 375.16% | HC Wainwright & Co. | $54 → $44 | Maintains | Buy |
03/17/2023 | 483.15% | HC Wainwright & Co. | → $54 | Reiterates | → Buy |
03/16/2023 | 245.57% | JP Morgan | $34 → $32 | Maintains | Overweight |
03/16/2023 | 256.37% | Wedbush | $45 → $33 | Maintains | Outperform |
05/13/2022 | 537.15% | SVB Leerink | $60 → $59 | Maintains | Outperform |
12/13/2021 | 483.15% | HC Wainwright & Co. | $37 → $54 | Maintains | Buy |
11/12/2021 | 483.15% | SVB Leerink | $55 → $54 | Maintains | Outperform |
08/13/2021 | 493.95% | SVB Leerink | $56 → $55 | Maintains | Outperform |
05/19/2021 | 385.96% | SVB Leerink | $60 → $45 | Maintains | Outperform |
05/05/2021 | 299.57% | HC Wainwright & Co. | → $37 | Initiates Coverage On | → Buy |
04/06/2021 | 547.95% | SVB Leerink | $37 → $60 | Maintains | Outperform |
11/19/2020 | 299.57% | SVB Leerink | $36 → $37 | Maintains | Outperform |
10/08/2020 | 385.96% | Baird | → $45 | Initiates Coverage On | → Outperform |
08/18/2020 | 331.97% | JP Morgan | → $40 | Initiates Coverage On | → Overweight |
08/18/2020 | 385.96% | Wedbush | → $45 | Initiates Coverage On | → Outperform |
08/18/2020 | 288.77% | SVB Leerink | → $36 | Initiates Coverage On | → Outperform |
08/18/2020 | 439.96% | Piper Sandler | → $50 | Initiates Coverage On | → Overweight |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
11/13/2023 | 213.17% | 摩根大通 | 32 美元 → 29 美元 | 維護 | 超重 |
2023 年 10 月 18 日 | 256.37% | Wedbush | → 33 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
08/09/2023 | 375.16% | HC Wainwright & Co. | 54 美元 → 44 美元 | 維護 | 買 |
03/17/2023 | 483.15% | HC Wainwright & Co. | → 54 美元 | 重申 | → 購買 |
03/16/2023 | 245.57% | 摩根大通 | 34 美元 → 32 美元 | 維護 | 超重 |
03/16/2023 | 256.37% | Wedbush | 45 美元 → 33 美元 | 維護 | 跑贏大盤 |
05/13/2022 | 537.15% | SVB Leerink | 60 美元 → 59 美元 | 維護 | 跑贏大盤 |
2021 年 12 月 13 日 | 483.15% | HC Wainwright & Co. | 37 美元 → 54 美元 | 維護 | 買 |
11/12/2021 | 483.15% | SVB Leerink | 55 美元 → 54 美元 | 維護 | 跑贏大盤 |
08/13/2021 | 493.95% | SVB Leerink | 56 美元 → 55 美元 | 維護 | 跑贏大盤 |
05/19/2021 | 385.96% | SVB Leerink | 60 美元 → 45 美元 | 維護 | 跑贏大盤 |
2021 年 5 月 5 日 | 299.57% | HC Wainwright & Co. | → 37 美元 | 啓動覆蓋範圍開啓 | → 購買 |
04/06/2021 | 547.95% | SVB Leerink | 37 美元 → 60 美元 | 維護 | 跑贏大盤 |
2020 年 11 月 19 日 | 299.57% | SVB Leerink | 36 美元 → 37 美元 | 維護 | 跑贏大盤 |
2020 年 8 月 10 日 | 385.96% | 貝爾德 | → 45 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
08/18/2020 | 331.97% | 摩根大通 | → 40 美元 | 啓動覆蓋範圍開啓 | → 超重 |
08/18/2020 | 385.96% | Wedbush | → 45 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
08/18/2020 | 288.77% | SVB Leerink | → 36 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
08/18/2020 | 439.96% | 派珀·桑德勒 | → 50 美元 | 啓動覆蓋範圍開啓 | → 超重 |
What is the target price for ITeos Therapeutics (ITOS)?
iTEOS Therapeutics(ITOS)的目標價格是多少?
The latest price target for ITeos Therapeutics (NASDAQ: ITOS) was reported by JP Morgan on November 13, 2023. The analyst firm set a price target for $29.00 expecting ITOS to rise to within 12 months (a possible 213.17% upside). 6 analyst firms have reported ratings in the last year.
摩根大通於2023年11月13日公佈了iTEOS Therapeutics(納斯達克股票代碼:ITOS)的最新目標股價。該分析公司將目標股價定爲29.00美元,預計ITOS將在12個月內升至12個月內(可能上漲213.17%)。去年有6家分析公司公佈了評級。
What is the most recent analyst rating for ITeos Therapeutics (ITOS)?
iTEOS Therapeutics(ITOS)的最新分析師評級是多少?
The latest analyst rating for ITeos Therapeutics (NASDAQ: ITOS) was provided by JP Morgan, and ITeos Therapeutics maintained their overweight rating.
摩根大通對iTeos Therapeutics(納斯達克股票代碼:ITOS)的最新分析師評級由摩根大通提供,iTEOS Therapeutics維持增持評級。
When is the next analyst rating going to be posted or updated for ITeos Therapeutics (ITOS)?
iTEOS Therapeutics(ITOS)的下一次分析師評級何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ITeos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ITeos Therapeutics was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與iTeos Therapeutics的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。iTeOS Therapeutics的最新評級是在2023年11月13日公佈的,因此您應該預計下一個評級將在2024年11月13日左右公佈。
Is the Analyst Rating ITeos Therapeutics (ITOS) correct?
分析師對iTEOS Therapeutics(ITOS)的評級是否正確?
While ratings are subjective and will change, the latest ITeos Therapeutics (ITOS) rating was a maintained with a price target of $32.00 to $29.00. The current price ITeos Therapeutics (ITOS) is trading at is $9.26, which is out of the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但最新的iTOS Therapeutics(ITOS)評級保持不變,目標股價爲32.00美元至29.00美元。iTEOS Therapeutics(ITOS)目前的交易價格爲9.26美元,超出了分析師的預期區間。